Page last updated: 2024-11-13

4-des-dimethylaminotetracycline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

4-des-dimethylaminotetracycline: non-antibacterial, inhibits mammalian collagenase; RN given refers to (4aS-(4aalpha,5aalpha,6beta,12aalpha))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54684440
MeSH IDM0151444

Synonyms (11)

Synonym
nsc118618
nsc-118618
4-des-dimethylaminotetracycline
2444-65-7
SRPCXEFYFVDUFQ-UHFFFAOYSA-N
4-de(dimethylamino)tetracycline
desdimethylaminotetracycline
dedimethylamine-tetracycline
3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-2-naphthacenecarboxamide #
2-naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-
2-naphthacenecarboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, [4as-(4a.alpha.,5a.alpha.,6.beta.,12a.alpha.)]-

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" In particular, recent simulation studies based on newly determined complex stability constants have drawn attention to the potential influence of Ca2+ and Mg2+ ions on the bioavailability of various TC derivatives in blood plasma."( Metal ion-tetracycline interactions in biological fluids. Part 8. Potentiometric and spectroscopic studies on the formation of Ca(II) and Mg(II) complexes with 4-dedimethylamino-tetracycline and 6-desoxy-6-demethyl-tetracycline.
Berthon, G; Decock-Le Révérend, B; Kozlowski, H; Lambs, L; Venturini, M, 1988
)
0.27

Dosage Studied

ExcerptRelevanceReference
" This nonsense mutation may cause a dosage difference of normal P0, and is probably underrepresented in the current mutation data bases."( Mild recurrent neuropathy in CMT1B with a novel nonsense mutation in the extracellular domain of the MPZ gene.
Ferrer, X; Lagueny, A; Latour, P; Le Masson, G; Rouanet, M; Vandenberghe, A; Vital, A; Vital, C, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (7.14)18.7374
1990's20 (71.43)18.2507
2000's6 (21.43)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]